Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Apr 21;64(5):e02067-19.
doi: 10.1128/AAC.02067-19. Print 2020 Apr 21.

Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

Guolan Wu  1   2 , Wenling Tang  3 , Duo Lv  1   2 , Lihua Wu  1   2 , Huili Zhou  1   2 , Xi Yang  4 , Yunliang Zheng  1   2 , You Zhai  1   2 , Jianzhong Shentu  5   2
Affiliations
Randomized Controlled Trial

Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

Guolan Wu et al. Antimicrob Agents Chemother. .

Abstract

The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC0-∞) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF. No unexpected safety or tolerability issues were observed.

Keywords: clinical pharmacokinetics; drug-drug interaction; morinidazole; organic anion transporter; tenofovir.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Study design.
FIG 2
FIG 2
Mean plasma concentration-time profiles of morinidazole (MOR) (A), M2 (B), M7 (C), M8-1 (D), and M8-2 (E) after intravenous infusion of morinidazole 500 mg in healthy Chinese subjects with or without pretreatment with TDF. Data expressed as means ± standard deviation (n = 15). M0, morinidazole.
FIG 3
FIG 3
Urinary excretion of morinidazole (MOR) and its major metabolites after intravenous infusion of morinidazole 500 mg, with or without pretreatment with TDF, in healthy Chinese subjects. Data expressed as means ± standard deviation (n = 15). Ae, amount of drug excreted; M0, morinidazole.
See this image and copyright information in PMC

References

    1. Cao C, Luo A, Wu P, Weng D, Zheng H, Wang S. 2017. Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial. Eur J Clin Microbiol Infect Dis 36:1225–1230. doi:10.1007/s10096-017-2913-z. - DOI - PubMed
    1. Lv A. October 2008 Usage of alpha-(morpholin-1-base) methyl-2-methyl-5-azathio-1-alcohol in preparation of anti-trichomoniasis and anti-ameba medicines. China patent ZL 200510134254.3.
    1. Gao R, Li L, Xie C, Diao X, Zhong D, Chen X. 2012. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Drug Metab Dispos 40:556–567. doi:10.1124/dmd.111.042689. - DOI - PubMed
    1. Zhong K, Li X, Xie C, Zhang Y, Zhong D, Chen X. 2014. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. Antimicrob Agents Chemother 58:4153–4161. doi:10.1128/AAC.02414-14. - DOI - PMC - PubMed
    1. Feng B, El-Kattan AF, Radi ZA. 2012. Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity. Curr Protoc Toxicol Chapter 23:unit 23.3.1-15. doi:10.1002/0471140856.tx2303s53. - DOI - PubMed

Publication types